Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2007;334:664-666 (31 March), doi:10.1136/bmj.39153.511701.BE
Hannah Brown, freelance journalist
Cambridge
Hannah@two-cultures.com
European proposals to allow drug companies to provide health information are meeting strong opposition. Hannah Brown explains the arguments
| The first 150 words of the full text of this article appear below. |
When, in 2002, the European parliament voted resoundingly against allowing drug companies to provide information about their products directly to patients, public health lobby groups thought that the matter had been firmly dismissed. However, five years on, the resurgence of intense discussions about the "liberalisation of patient information," as the European Commission refers to it, suggests that parliament's resolve is set to be challenged again.
At issue is a set of proposals for relaxing the current laws that limit drug companies' communication with patients to the fixed format safety summary contained inside drug packaging. For the commission, which drafts European Union legislation, this debate is a trade-off between nurturing the competitiveness of one of the EU's biggest industries and respecting the concerns of public health organisations. What worries campaign groups most is that the commission seems to be ignoring them.
Hard lobbying by the drug industry has convinced the EU
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
StumbleUpon
Technorati What's this?
Read all Rapid Responses